Medicare beneficiaries do not pay coinsurance for CRC screenings. However, if the gastroenterologist identifies a polyp for removal, the screening becomes a diagnostic test, which does include coinsurance.
The proposed 2022 Physician Fee Schedule, issued July 13, gradually would reduce the percentage of coinsurance when CRC screenings become diagnostic tests over the next decade. Beneficiaries would be responsible for 20 percent in 2022, 15 percent in 2023 to 2026, and 10 percent in 2027 to 2029.
By 2030, coinsurance would be eliminated for Medicare beneficiaries who undergo a CRC screening that becomes a diagnostic test.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.